Literature DB >> 27549815

Ganoderic Acid A Targeting β-Catenin in Wnt Signaling Pathway: In Silico and In Vitro Study.

Balraj Singh Gill1, Sanjeev Kumar1.   

Abstract

Wnt signaling pathways are the group of signaling transduction controlling the embryonic development, cell proliferation, cell migration, cell fate specification, and body axis pattern. Nuclear accumulation of β-catenin in Wnt signaling is a widely recognized marker of poor cancer prognosis which regulates fat and glucose metabolism. Ganoderic acid is a triterpene isolated from fungus Ganoderma lucidum renowned for its pharmacological effects. The present study revealed the mechanistic study of β-catenin with 50 isoforms of ganoderic acid by molecular docking using Maestro 9.6 (Schrödinger Inc) in Wnt signaling pathway. Molecular docking reveals the binding interaction of β-catenin and ganoderic acid A with GScore (-9.44), kcal/mol, lipophilic EvdW (-2.86), electro (-0.72), Glide emodel (-50.401), MM-GBSA (-87.441), H bond (-1.91) with Lys 180 and Asn 220 residues involved in hydrogen bonding. Qikprop analyzed the absorption, distribution, metabolism, excretion, and toxicity and confirmed that most of the isoforms satisfies Lipinski rule but needs little modifications in their structure. The ganoderic acid A is the best-docked isoforms which inhibits the proliferation, viability, and intracellular ROS of pancreatic cancer RIN-5F cells in a dose-dependent manner.

Entities:  

Keywords:  Diabetes II; Ganoderic acid; Molecular docking; Wnt signaling; β-catenin

Mesh:

Substances:

Year:  2016        PMID: 27549815     DOI: 10.1007/s12539-016-0182-7

Source DB:  PubMed          Journal:  Interdiscip Sci        ISSN: 1867-1462            Impact factor:   2.233


  6 in total

Review 1.  Ganoderic acid, lanostanoid triterpene: a key player in apoptosis.

Authors:  Balraj Singh Gill; Richa Mehra; Vicky Kumar; Sanjeev Kumar
Journal:  Invest New Drugs       Date:  2017-10-28       Impact factor: 3.850

2.  Ganoderic acid targeting multiple receptors in cancer: in silico and in vitro study.

Authors:  Balraj Singh Gill; Sanjeev Kumar
Journal:  Tumour Biol       Date:  2016-09-03

3.  Pharmacokinetic, Metabolomic, and Stability Assessment of Ganoderic Acid H Based Triterpenoid Enriched Fraction of Ganoderma lucidum P. Karst.

Authors:  Mohd Hafizur Rehman Ansari; Washim Khan; Rabea Parveen; Sadia Saher; Sayeed Ahmad
Journal:  Metabolites       Date:  2022-01-21

4.  GSNOR regulates ganoderic acid content in Ganoderma lucidum under heat stress through S-nitrosylation of catalase.

Authors:  Rui Liu; Ting Zhu; Xin Chen; Zi Wang; Zhengyan Yang; Ang Ren; Liang Shi; Hanshou Yu; Mingwen Zhao
Journal:  Commun Biol       Date:  2022-01-11

5.  Sdy-1 Executes Antitumor Activity in HepG2 and HeLa Cancer Cells by Inhibiting the Wnt/β-Catenin Signaling Pathway.

Authors:  Mengyu Sun; Dongdong Zhou; Jingwan Wu; Jing Zhou; Jing Xu
Journal:  Mar Drugs       Date:  2022-02-05       Impact factor: 5.118

6.  Associated Targets of the Antioxidant Cardioprotection of Ganoderma lucidum in Diabetic Cardiomyopathy by Using Open Targets Platform: A Systematic Review.

Authors:  Fahmi Shaher; Hongbin Qiu; Shuqiu Wang; Yu Hu; Weiqun Wang; Yu Zhang; Yao Wei; Hisham Al-Ward; Mahfoudh A M Abdulghani; Sattam Khulaif Alenezi; Salem Baldi; Shaobo Zhou
Journal:  Biomed Res Int       Date:  2020-07-25       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.